Levosimendan

Generic Name: Levosimendan

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₂N_₆O

CAS Number: 141505-33-1

Unique Ingredient Identifier: C6T4514L4E

Background: Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.

Indication: For short term treatment of acutely decompensated severe chronic heart failure (CHF). Also being investigated for use/treatment in heart disease.

Associated Conditions: Acute Decompensated Heart Failure (ADHF), Acute Decompensation of Chronic Heart Failure, Acute Heart Failure (AHF), Chronic Heart Failure (CHF), Acute post-surgical heart failure, Acute, chronic Decompensated Heart Failure, Heart failure post-myocardial infarction, Severe Decompensated Chronic Heart Failure

Associated Therapies: Positive cardiac inotropic effect, Intravenous inotropic therapy

Clinical Trials

Interest of Levosimendan Preconditioning for Cardiac Surgery Under CEC in Heart Failure Patients With Impaired Ejection Fraction

Recruiting

Conditions: Levosimendan
Heart Failure With Reduced Ejection Fraction
Cardiac Surgery

Interventions: Drug: No Levosimendan
Drug: Levosimendan

First Posted Date: 2023-09-01

Last Posted Date: 2023-09-01

Lead Sponsor: Central Hospital, Nancy, France

Target Recruit Count: 300

Registration Number: NCT06021587

Locations: 🇫🇷
'CHRU Nancy, Vandœuvre-lès-Nancy, Meurthe Et Moselle, France

RCT Study of Levosimendan Improving Prognosis of Cardiac Arrest

Phase 4

Not yet recruiting

Conditions: Heart Arrest

Interventions: Drug: physiological saline
Drug: Levosimendan Injection

First Posted Date: 2023-07-21

Last Posted Date: 2023-07-21

Lead Sponsor: Peking University Third Hospital

Target Recruit Count: 60

Registration Number: NCT05956431

Using TEE to Evaluate the Effect of Levosimendan on Patients With ARDS Associated With RVD During MV

Phase 2

Not yet recruiting

Conditions: Acute Respiratory Distress Syndrome
Transesophageal Echocardiography
Right Ventricular Dysfunction

Interventions: Drug: 5% glucose injection
Drug: levosimendan

First Posted Date: 2023-03-14

Last Posted Date: 2023-03-14

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 58

Registration Number: NCT05768230

Locations: 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Efficacy and Clinical Outcomes of Levosimendan in E-CPR

Recruiting

Conditions: Cardiogenic Shock
Extracorporeal Membrane Oxygenation Complication

First Posted Date: 2023-02-16

Last Posted Date: 2023-02-16

Lead Sponsor: Hamad Medical Corporation

Target Recruit Count: 100

Registration Number: NCT05730907

Locations: 🇶🇦
Hamad medical corporation, Doha, DA, Qatar

Impact of Levosimendan Preconditioning on Critical Care and In-hospital Lengths of Stay After Cardiac Surgery With Bypass Surgery

Recruiting

Conditions: Cardiopulmonary Bypass
Levosimendan
Cardiac Surgery

Interventions: Drug: Levosimendan

First Posted Date: 2023-01-17

Last Posted Date: 2023-01-17

Lead Sponsor: Central Hospital, Nancy, France

Target Recruit Count: 120

Registration Number: NCT05685537

Locations: 🇫🇷
'CHRU Nancy, Vandœuvre-lès-Nancy, Meurthe Et Moselle, France

Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage

Phase 2

Recruiting

Conditions: Sub-arachnoid Haemorrhage

Interventions: Other: Placebo
Drug: Levosimendan

First Posted Date: 2022-12-23

Last Posted Date: 2024-02-16

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 30

Registration Number: NCT05664191

Locations: 🇫🇷
Hôpital Lariboisière, Service d'anesthésie Réanimation, Paris, France

Levosimendan Versus Placebo Before Tricuspid Valve Surgery in Patients With Right Ventricular Dysfunction

Phase 3

Recruiting

Conditions: Patients Referred for an Isolated or a Combined Surgical Correction of Functional Moderate to Severe Tricuspid

Interventions: Drug: PLACEBO
Drug: Levosimendan

First Posted Date: 2022-02-10

Last Posted Date: 2023-05-15

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 230

Registration Number: NCT05233202

Locations: 🇫🇷
Assistance Publique Hôpitaux de Paris-Hôpital Henri Mondor, Créteil, France

Comparison Between Levosimendan and Adrenaline in CABG Patients

Not Applicable

Conditions: Open Heart Surgery

Interventions: Drug: Adrenaline
Drug: Levosimendan

First Posted Date: 2022-02-03

Last Posted Date: 2022-02-08

Lead Sponsor: Assiut University

Target Recruit Count: 52

Registration Number: NCT05222256

Levosimendan in Patients With Impaired Right Ventricular Function Undergoing Cardiac Surgery

Phase 2

Conditions: Right Heart Failure
Open-heart Surgery

Interventions: Drug: Standard Care
Drug: Levosimendan

First Posted Date: 2021-10-01

Last Posted Date: 2021-10-20

Lead Sponsor: Ain Shams University

Target Recruit Count: 40

Registration Number: NCT05063370

Locations: 🇪🇬
Cardiothoracic Academy, Ain Shams University Hospitals, Cairo, Egypt

Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction

Phase 4

Conditions: ST Elevation Myocardial Infarction
Heart Failure

Interventions: Other: placebo
Drug: Levosimendan

First Posted Date: 2021-07-21

Last Posted Date: 2021-08-20

Lead Sponsor: Zhijun Sun

Target Recruit Count: 500

Registration Number: NCT04970238

Locations: 🇨🇳
Shengjing Hospital, Shenyang, Liaoning, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy